Menu

AACR Q&A: Elaine Mardis

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

Apr 18, 2016
The Scientist Staff

COURTESY OF ELAINE MARDIS

The American Association for Cancer Research (AACR) annual meeting is huge—so big that it can be tough to choose which talks to attend in person (or tune in to from afar). The Scientist asked Washington University in St. Louis’s Elaine Mardis—who is on the planning committee for this year’s conference, being held in New Orleans—to share her picks of the most buzzworthy topics in cancer research today.

The Scientist: To your mind, what are some of the hottest areas of cancer research right now?

Elaine Mardis: Immunotherapy and immunogenomics, liquid biopsy-based monitoring of patient response to therapy, [and] clinical genomic assays to identify therapeutic targets.

TS:  What are you presenting at AACR this year?  

EM: I am speaking in the opening plenary about cancer genomics and its transition to aid patient care in the cancer clinic. I also am providing a wrap-up of the cancer prevention and early detection work [being] presented at the meeting this year.                

TS: What new topics are emerging that have received less attention in past conferences?

EM: Liquid biopsy and early detection of cancers. Germline contribution of cancer susceptibility mutations in patients without a family history of cancer.

TS: What talks or posters do you anticipate finding most exciting?

EM: I think the Wednesday plenary lectures on single-cell genomics and the tumor heterogeneity plenary on Tuesday will have the most exciting talks.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.